

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818338/>

Curr Opin Pharmacol. Author manuscript; available in PMC 2011 February 1.

Published in final edited form as:

Curr Opin Pharmacol. 2010 February; 10(1): 80.

Published online 2009 October 25. doi: [10.1016/j.coph.2009.09.009](https://doi.org/10.1016/j.coph.2009.09.009)

PMCID: PMC2818338

NIHMSID: NIHMS154993

## Cannabinoid-opioid interactions during neuropathic pain and analgesia

Ittai Bushlin,<sup>1</sup> Raphael Rozenfeld,<sup>1</sup> and Lakshmi A Devi<sup>1</sup>

[Author information](#) ► [Copyright and License information](#) ►

The publisher's final edited version of this article is available at [Curr Opin Pharmacol](#)

See other articles in PMC that [cite](#) the published article.

### Abstract

---

Opiates and exogenous cannabinoids, both potent analgesics used for the treatment of patients with neuropathic pain, bind to and activate class A G-protein coupled receptors (GPCRs). Several lines of evidence have recently suggested that opioid and cannabinoid receptors can functionally interact in the central nervous system (CNS). These interactions may be direct, such as through receptor heteromerization, or indirect, such as through signaling cross-talk that includes agonist-mediated release and/or synthesis of endogenous ligands that can activate downstream receptors. Interactions between opioid and cannabinoid receptors may mediate many of the behavioral phenomena associated with use of these drugs, including the production of acute antinociception and the development of tolerance and cross-tolerance to the antinociceptive effects of opioid and cannabinoid-specific ligands. This review summarizes behavioral, anatomical, and molecular data characterizing these interactions during the development of neuropathic pain and during antinociceptive treatment with these drugs alone or in combination. These studies are critical for understanding how the receptor systems involved in pain relief are altered during acute or chronic pain, and for designing better antinociceptive drug therapies, such as the combined use of opioid and cannabinoid receptor agonists or selective activation of receptor heteromers, that directly target the altered neurophysiology of patients experiencing pain.

### Introduction

---

## Neuropathic pain

In the United States alone, over 2 million people suffer chronic and debilitating neuropathic pain as a result of trauma or disease affecting the peripheral or central nervous system (CNS) [1]. Common causes of neuropathic pain include diabetic neuropathy, nerve compression syndromes, postherpetic or trigeminal neuralgia, stroke, multiple sclerosis and spinal cord injury [2]. Clinically, neuropathic pain has both a sensory discriminative component, manifested in part as allodynia (an abnormally painful response to normally innocuous stimuli) and hyperalgesia (an exaggerated response to painful stimuli), and an affective component characterized by heightened anxiety and depression, diminished motivation, and changes in motor control [3,4]. Treatment of neuropathic pain is difficult and controversial; however, both components of neuropathic pain are affected significantly by administration of opiates such as morphine and exogenous cannabinoids such as  $\Delta^9$ tetrahydrocannabinol (THC), compounds that have analgesic and addictive properties [1]. These observations suggest that there are functional interactions between the endogenous cannabinoid and opioid receptor systems, both of which are altered during neuropathic pain [5], in the modulation of nociceptive processing. This review focuses on recent work detailing interactions between these receptor systems during peripheral nerve injury and during production of antinociception. These studies are crucial for understanding the pathophysiological response of the CNS to a peripheral nerve injury and for designing new treatments that will optimize the analgesic effects of receptor-specific ligands while minimizing undesirable side effects such as development of tolerance and reward.

## Common features of opioid and cannabinoid receptor systems

There is considerable behavioral, anatomical and biochemical evidence describing similarities between the opioid receptor system – which includes three subtypes of receptors, mu, delta and kappa (MOR, DOR, and KOR) and the endogenous opioid peptides that can activate these receptors, beta-endorphin, enkephalin, and dynorphin (for review see [6]) – and the cannabinoid receptor system – which comprises the two major cannabinoid receptors, CB<sub>1</sub>R and CB<sub>2</sub>R, and their endogenous ligands, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), both lipid-derived messengers (for review see [7]). Activation of opioid or cannabinoid receptors can produce similar behavioral effects, including antinociception, hypothermia, sedation, hypotension, inhibition of intestinal motility and motor depression [8], suggesting a similar distribution and mechanism of action. Both receptor types are found in several brain regions known to participate in antinociception, including periaqueductal gray (PAG), raphe nuclei and central-medial thalamic nuclei [9], suggesting that they may either act alone, or in tandem to produce antinociception. Furthermore, MOR and CB<sub>1</sub>R have been shown to co-localize to the same neurons within the superficial dorsal horn of the spinal cord [10,11], the first site of synaptic contact for peripheral nociceptive afferents, raising the possibility of direct interactions between these receptor types within the same cell.

Opioid and cannabinoid receptors also share similar signal transduction properties. Both are GPCRs that 1) couple to  $G\alpha_i$ , blocking cAMP production, 2) activate MAP kinases through other second messenger systems, and 3) inhibit neurotransmitter release via inhibition of calcium channels and activation of potassium channels [7,9,12]. Both receptor types are generally found on presynaptic terminals, a location that is consistent with the inhibition of neurotransmitter release [12]. These data raise the intriguing possibility that opioid and cannabinoid receptors function together within the same cell or neuronal circuit to produce antinociception and that modulation of one receptor system may lead to alterations in the activity of the other.

Activation of both opioid and cannabinoid receptors with selective agonists can lead to antinociception in animals experiencing neuropathic pain [5]. Several groups have examined whether both receptor systems are required for the production of antinociception by exogenous drug treatment. THC-induced antinociception was not modified in MOR, DOR, or KOR knockout mice [13], or in MOR-DOR knockout mice [14] while, morphine-induced antinociception was not modified in CB<sub>1</sub>R knockout mice [15]. In addition, antinociception induced by DOR or KOR selective agonists was not altered in CB<sub>1</sub>R knockout mice [15]. Therefore, selective agonists to opioid and cannabinoid receptors only require the presence of their respective receptor to produce antinociceptive effects. However, in wild-type animals considerable evidence has demonstrated the involvement of the endogenous opioid system in the production of antinociception by exogenous cannabinoid agonist treatment and vice versa, as described below.

### **Opioid/cannabinoid interactions in the production of antinociception by exogenous drug treatment**

Studies in intact animals have examined opioid/cannabinoid receptor interactions during antinociceptive drug treatment by three main approaches, including: using selective antagonists to one receptor to evaluate alterations in antinociception produced by selective agonists to the other receptor; measuring the development of cross-tolerance to opioid and cannabinoid agonists; and evaluating synergistic interactions between drugs that activate these receptors. Results using receptor antagonists were initially controversial. While naloxone, a general opioid receptor antagonist, was reported to block THC-induced antinociception on the tail-flick test, relatively high doses of naloxone, doses that may have caused off-target effects, were used in these studies [8]. Additional studies done with lower doses of selective antagonists against opioid receptor subtypes or using antisense oligos (to KOR) clarified that MOR and KOR, but not DOR, are involved in the antinociceptive effects of THC [8]. These results imply that treatment with THC or other cannabinoid receptor agonists that do not bind to or activate opioid receptors leads to release of endogenous opioid peptides that activate MOR and KOR. In support of this hypothesis, it has been reported that intrathecal administration of the cannabinoid receptor agonists THC or CP 55,490 leads to dynorphin B release in the spinal cord and that antisera to dynorphin can

block THC-induced antinociception [16–19]. Prodynorphin knockout mice show a reduction in THC induced antinociception [12]. The role of opioid peptide release in cannabinoid-mediated antinociception was further supported by a study that demonstrated that inhibitors of opioid degrading enzymes are able to potentiate THC-induced antinociception [20]. Moreover, THC administered over 5 days leads to increases in preproenkephalin expression in the spinal cord, PAG and striatum, increases in prodynorphin gene expression in the spinal cord and increases in proopioidmelanocortin (POMC) gene expression in the hypothalamus [21–23]. Together, these data suggest that acute administration of cannabinoid receptor agonists can lead to opioid peptide release and that chronic THC administration increases endogenous opioid precursor gene expression.

Interactions between endogenous cannabinoid ligands, or “endocannabinoids”, and the endogenous opioid system during antinociception have been evaluated using cannabinoid receptor antagonists, or using inhibitors of enzymes that degrade endocannabinoids. The CB<sub>1</sub>R antagonist AM251 can reverse morphine-induced, but not DOR agonist-induced, peripheral antinociception in an inflammatory pain model [24] or central antinociception in an acute thermal pain model [25], indicating that endocannabinoid activity may be critical for morphine’s actions. Several groups have reported that the antihyperalgesic effects of inhibitors of fatty acid amide hydrolase (FAAH), the enzyme that degrades AEA, can be blocked by naloxone or nor-BNI, the KOR antagonist [26,27]. These results support the hypothesis that increasing endocannabinoid levels using inhibitors of endocannabinoid degradation elicits antinociception by a similar mechanism as direct activation of CB<sub>1</sub>R with THC or CP 55,490 – through the release of endogenous opioid peptides. This effect may not be restricted to CB<sub>1</sub>R – one report recently demonstrated that direct activation of CB<sub>2</sub>R, the cannabinoid receptor generally thought to be localized to the periphery, can induce antinociception via release of endogenous opioid peptides, such as beta-endorphin [28].

### **Cross-tolerance between exogenous agonists**

A considerable number of studies have examined bidirectional cross-tolerance between opioid and cannabinoid agonists in eliciting antinociceptive effects, though these results are conflicting. One study reported that morphine-dependent animals show decreased antinociceptive responses to THC [29], while others reported that THC or CP 55,490 can potentiate acute antinociception in morphine-tolerant animals [30,31]. These behavioral findings cannot be explained solely based on changes in cannabinoid receptor expression, as CB<sub>1</sub>R density in the spinal cord does not change in animals showing cross-tolerance to THC, and CB<sub>1</sub>R density is alternatively reported to decrease [31] or increase [30] in animals showing sensitization to THC. . Other mechanisms such as cross desensitization or G-protein sequestration could account for cross tolerance to THC [32]. Reciprocal studies, evaluating the effects of chronic cannabinoid treatment on opioid receptor expression, have shown that cannabinoid tolerance is associated with a slight increase in MOR protein in several brain areas [33]. This result is somewhat counterintuitive in light of studies showing

that antinociception to morphine is reduced in animals made tolerant to the antinociceptive effects of CP 55,490 [12].

Genetic studies have yielded less ambiguous results – tolerance to the antinociceptive effects of THC is not altered in MOR and DOR knockout animals, and tolerance to the antinociceptive effects of morphine is not altered in CB<sub>1</sub>R knockout animals [34]. This suggests that tolerance to exogenous opioids does not depend on the presence of cannabinoid receptors and that tolerance to exogenous cannabinoids does not depend on the presence of opioid receptors. However, preproenkephalin knockout animals show a decrease in THC-induced antinociception and a decrease in the development of tolerance to the antinociceptive effects of THC [35]. Thus, both acute antinociception and development of tolerance induced by THC may be associated with endogenous opioid peptide release.

### **Synergism between opioid and cannabinoid receptor agonists**

Though opioid agonists such as morphine are commonly used for patients with chronic pain, these treatments are limited by the development of tolerance as well as the deleterious side effects of high doses of opioids, including constipation and respiratory depression. Thus, combination treatment of low doses of cannabinoid agonists alongside opioid agonists is particularly attractive. Several groups have reported additive effects between agonists of these two classes, though effects may be compound specific and correct pairing of the most effective combinations is essential [9,36]. For example, CP 55,490 enhances morphine antinociception when administered intrathecally or intraperitoneally while AEA does not [9], likely because it is quickly degraded. Interestingly, opioid receptor protein is upregulated after chronic treatment with low doses of THC and morphine [37], which may underlie the antinociceptive synergism between these two agonists.

### **Changes in expression of opioid and cannabinoid receptors during neuropathic pain**

Changes in receptor expression, function, and degree of interaction may underlie altered responsiveness to antinociceptive drug treatment during chronic pain syndromes [38]. A number of studies have compared alterations in the expression and function of opioid and cannabinoid receptors during the development of neuropathic pain (see Table 1). While CB<sub>1</sub>R levels have been reported to increase in ipsilateral spinal cord [39–41], or in contralateral thalamus [42] after chronic constriction injury, spinal nerve ligation, or spared nerve injury (see Table 2), reports of changes in opioid receptor expression during neuropathic pain vary with the pain model used. Decreases in MOR in the spinal cord and dorsal root ganglion (DRG) are associated with peripheral nerve lesion [38,43,44], while increases at the lesion site or in DRG are observed during inflammatory pain [45]. DOR expression and G-protein coupling are decreased or unchanged in spinal cord and DRG [43,46–49], while KOR expression is reportedly unchanged or slightly increased in these tissues [50]. Together these data suggest changes in receptor expression during neuropathic pain that are pain-model specific. It is interesting to note that CB<sub>1</sub>R expression increases

while MOR expression decreases in the spinal cord after peripheral nerve lesion suggesting that the increase in CB<sub>1</sub>R expression could be due to a compensatory role of this receptor.

Pain Model	Region examined (all ipsilateral, unless specified)	Receptor	Direction of change
Paw inflammation	Spinal cord, dorsal horn	MOR	+ <sup>2</sup> [20] - <sup>3</sup> [43,60,61]
		DOR	- [43,59-61]
		KOR	+ [20] - [43,60,61]
	DRG	MOR	+ [43] - [43]
		DOR	- [43,45]
		KOR	- [43]
Chronic constriction injury	Spinal cord, dorsal horn	MOR	+ [20] - [43], + <sup>1</sup> [40]

**Table 1**

Changes in opioid receptor levels in nervous system during neuropathic pain

Pain Model	Region examined (all ipsilateral, unless specified)	Receptor	Direction of change
Paw inflammation	Spinal cord, dorsal horn	CB <sub>1</sub> R	- <sup>2</sup> [71]
Chronic constriction injury	Spinal cord, dorsal horn	CB <sub>1</sub> R	+ <sup>2</sup> [23]
Axotomy of sciatic nerve (tibial branch)	Contralateral thalamus	CB <sub>1</sub> R	+ [71]
		CB <sub>2</sub> R	+ [42]
Lumbar spinal nerve ligation	DRG	CB <sub>1</sub> R	+ [41]
		CB <sub>2</sub> R	+ [71]

**Table 2**

Changes in cannabinoid receptor levels in nervous system during neuropathic pain

### Functional interactions at the cellular level

Evidence from electron microscopy studies has demonstrated co-localization of CB<sub>1</sub>R and MOR in the same neuron [10,11,51,52], raising the possibility of direct interactions between these receptors. Consequently, several groups have evaluated functional interactions between opioid and cannabinoid receptors in brain tissues and within *in vitro* systems. Studies using whole brain or cortical membranes found that application of THC leads to an increase in the dissociation of MOR and DOR-specific ligands [53,54], demonstrating that THC can act as an allosteric modulator of opioid receptor binding. Functional interactions between CB<sub>1</sub>R and DOR receptors have also been evaluated in N18TG2 cells, which endogenously co-express these receptors. Chronic treatment of N18TG2 cells with either etorphine, an opioid agonist, or DALN, a cannabinoid agonist, leads to agonist-induced desensitization to the respective drug [55]. However, long term exposure to etorphine reduces the ability of DALN to activate cannabinoid receptors – evidence for cross-desensitization [55]. This effect is not reciprocal, as long term exposure to DALN does not reduce the ability of etorphine to activate opioid receptors [55]. These data provide evidence for cross-tolerance between opioid and cannabinoid receptors in an *in vitro* system. Together, these data demonstrate functional and sometimes bidirectional interactions between opioid and cannabinoid receptors within cells known to contain both receptors.

These interactions may underlie the cross-tolerance and synergism associated with antinociceptive treatment using combinations of ligands.

## Conclusions and future directions

---

Opioid and cannabinoid receptor specific agonists are potent analgesics and remain among the more effective treatments for patients with neuropathic pain. However, tolerance and cross-tolerance can develop quickly to the antinociceptive actions of these drugs, limiting their long-term use. The molecular correlates of cross-tolerance remain unclear – changes in receptor density, thought to be markers of receptor responsiveness, are not directly associated with the development of cross-tolerance and may be pain-model specific. Studies showing that treatment with cannabinoid receptor agonists can lead to opioid peptide release and that endocannabinoids are involved in the actions of opioid agonists underscore the synergistic interactions between these two receptor systems. Indeed, combination therapy with acute or subacute doses of opioid and cannabinoid receptor agonists may be an alternative way to circumvent the undesirable side effects of these drugs.

Another strategy is to directly target receptor heteromers, which have emerged as new candidates for antinociceptive therapy. Recent studies have demonstrated that opioid and cannabinoid receptors heteromerize in membranes of co-transfected cells [56], and that CB<sub>1</sub>R-DOR and CB<sub>1</sub>R-KOR can form heteromers as well [56]. Signaling responses to a CB<sub>1</sub>R agonist are attenuated in the presence of a MOR agonist, and vice versa, in co-transfected cells and in endogenous tissue expressing CB<sub>1</sub>R and MOR, indicating that the association between these receptors leads to an antagonistic response. It follows that a bivalent drug that simultaneously activates one receptor protomer while blocking the activity of the other receptor protomer could be an effective analgesic. To date, such compounds have been designed against MOR-DOR or DOR-KOR heteromers [57,58], but not against opioid-cannabinoid receptor complexes; these compounds should be created and tested. Together, the strategies of using combination treatment of opioid and cannabinoid agonists or directly targeting receptor heteromers are two exciting avenues of research that need to be more fully explored, but that have tremendous potential for reducing chronic pain.

## Acknowledgements

---

This work is supported by NIH grants DA08863 and DA19521 to Lakshmi A. Devi. Ittai Bushlin is a trainee in the Integrated Pharmacological Sciences Training Program supported by grant T32GM062754 from the National Institute of General Medical Sciences.

## References and Recommended Reading

---

Papers of particular interest, published within the period of review, have been highlighted as:

- of special interest

•• of outstanding interest

1. Foley KM. Opioids and chronic neuropathic pain. *N Engl J Med.* 2003;348:1279–1281. [[PubMed](#)]
2. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. *Jama.* 2005;293:3043–3052. [[PubMed](#)]
3. Finnerup NB, Sindrup SH, Jensen TS. Chronic neuropathic pain: mechanisms, drug targets and measurement. *Fundam Clin Pharmacol.* 2007;21:129–136. [[PubMed](#)]
4. Jensen MP, Hoffman AJ, Cardenas DD. Chronic pain in individuals with spinal cord injury: a survey and longitudinal study. *Spinal Cord.* 2005;43:704–712. [[PubMed](#)]
5. Welch SP. Interaction of the cannabinoid and opioid systems in the modulation of nociception. *Int Rev Psychiatry.* 2009;21:143–151. [[PubMed](#)]
6. Kieffer BL. Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. *Cell Mol Neurobiol.* 1995;15:615–635. [[PubMed](#)]
7. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. *Pharmacol Rev.* 2002;54:161–202. [[PubMed](#)]
8. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. *Trends Pharmacol Sci.* 1999;20:287–294. [[PubMed](#)]
9. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. *Life Sci.* 2004;74:1317–1324. [[PubMed](#)]
10. Hohmann AG, Briley EM, Herkenham M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. *Brain Res.* 1999;822:17–25. [[PubMed](#)]
11. Salio C, Fischer J, Franzoni MF, Mackie K, Kaneko T, Conrath M CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. *Neuroreport.* 2001;12:3689–3692. [[PubMed](#)]
- This study shows the co-localization of CB<sub>1</sub>R and MOR on individual neurons within the dorsal horn the spinal cord, by immuno electron-microscopy
12. Vigano D, Rubino T, Parolaro D. Molecular and cellular basis of cannabinoid and opioid interactions. *Pharmacol Biochem Behav.* 2005;81:360–368. [[PubMed](#)]

13. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. *J Neurosci.* 2002;22:1146–1154. [[PubMed](#)]
14. Castane A, Robledo P, Matifas A, Kieffer BL, Maldonado R. Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. *Eur J Neurosci.* 2003;17:155–159. [[PubMed](#)]
15. Valverde O, Ledent C, Beslot F, Parmentier M, Roques BP. Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors. *Eur J Neurosci.* 2000;12:533–539. [[PubMed](#)]
16. Houser SJ, Eads M, Embrey JP, Welch SP. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide. *Brain Res.* 2000;857:337–342. [[PubMed](#)]
17. Mason DJ, Jr, Lowe J, Welch SP. Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception. *Eur J Pharmacol.* 1999;378:237–248. [[PubMed](#)]
18. Pugh G, Jr, Mason DJ, Jr, Combs V, Welch SP. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord. *J Pharmacol Exp Ther.* 1997;281:730–737. [[PubMed](#)]
19. Smith PB, Welch SP, Martin BR. Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice. *J Pharmacol Exp Ther.* 1994;268:1381–1387. [[PubMed](#)]
20. Reche I, Ruiz-Gayo M, Fuentes JA. Inhibition of opioid-degrading enzymes potentiates delta9-tetrahydrocannabinol-induced antinociception in mice. *Neuropharmacology.* 1998;37:215–222. [[PubMed](#)]
21. Corchero J, Avila MA, Fuentes JA, Manzanares J. delta-9-Tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat. *Life Sci.* 1997;61:PL 39–PL 43. [[PubMed](#)]
22. Corchero J, Fuentes JA, Manzanares J. delta 9-Tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus. *Eur J Pharmacol.* 1997;323:193–195. [[PubMed](#)]
23. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA. Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. *Brain Res Mol Brain Res.* 1998;55:126–132. [[PubMed](#)]
24. da Fonseca Pacheco D, Klein A, de Castro Perez A, da Fonseca Pacheco CM, de Francischi JN, Duarte ID The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors. *Br J Pharmacol.* 2008;154:1143–1149. [[PubMed](#)]

•• Cannabinoids participate in the antinociceptive actions of morphine - blocking CB<sub>1</sub>R with the selective antagonist AM251 abolishes the antinociceptive effects of morphine in a peripheral inflammatory pain model.

25. da Fonseca Pacheco D, Klein A, Perez AC, da Fonseca Pacheco CM, de Francischi JN, Lopes Reis GM, Duarte ID. Central antinociception induced by micro-opioid receptor agonist morphine, but not delta- or kappa-, is mediated by cannabinoid CB receptor. *Br J Pharmacol.* 2009;158:225–231. [[PMC free article](#)] [[PubMed](#)]

26. Jhaveri MD, Richardson D, Kendall DA, Barrett DA, Chapman V Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. *J Neurosci.* 2006;26:13318–13327. [[PubMed](#)]

•• Use of FAAH inhibitors to Increase endocannabinoid levels in the spinal cord attenuates mechanical pain in an animal experiencing neuropathic pain. Interestingly, the authors demonstrate the role of opioid receptors (and endogenous opioid peptides by extension) in the antinociceptive effects of FAAH inhibitors as these effects can be blocked by naloxone.

27. Schlosburg JE, Kinsey SG, Lichtman AH. Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. *Aaps J.* 2009;11:39–44. [[PMC free article](#)] [[PubMed](#)]

28. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, Davar G, Makriyannis A, Vanderah TW, Mata HP, et al. CB<sub>2</sub> cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. *Proc Natl Acad Sci U S A.* 2005;102:3093–3098. [[PubMed](#)]

• This elegant study demonstrates that the antinociceptive actions of a CB<sub>2</sub>R agonist can be blocked by anti-serum to beta-endorphin and that a CB<sub>2</sub>R can lead to beta-endorphin release from keratinocytes. This supports a role for endogenous opioid peptide release in the antinociceptive actions of cannabinoid receptor agonists.

29. Thorat SN, Bhargava HN. Evidence for a bidirectional cross-tolerance between morphine and delta 9-tetrahydrocannabinol in mice. *Eur J Pharmacol.* 1994;260:5–13. [[PubMed](#)]

30. Rubino T, Tizzoni L, Vigano D, Massi P, Parolaro D. Modulation of rat brain cannabinoid receptors after chronic morphine treatment. *Neuroreport.* 1997;8:3219–3223. [[PubMed](#)]

31. Vigano D, Rubino T, Vaccani A, Bianchessi S, Marmorato P, Castiglioni C, Parolaro D. Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. *Psychopharmacology (Berl)* 2005;182:527–536. [[PubMed](#)]

32. Vasquez C, Lewis DL. The CB<sub>1</sub> cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. *J Neurosci.* 1999;19:9271–9280. [[PubMed](#)]

33. Robledo P, Berrendero F, Ozaita A, Maldonado R. Advances in the field of cannabinoid--opioid cross-talk. *Addict Biol.* 2008;13:213–224. [[PubMed](#)]
34. Maldonado R, Valverde O. Participation of the opioid system in cannabinoid-induced antinociception and emotional-like responses. *Eur Neuropsychopharmacol.* 2003;13:401–410. [[PubMed](#)]
35. Valverde O, Maldonado R, Valjent E, Zimmer AM, Zimmer A. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. *J Neurosci.* 2000;20:9284–9289. [[PubMed](#)]
36. Tham SM, Angus JA, Tudor EM, Wright CE Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice. *Br J Pharmacol.* 2005;144:875–884. [[PubMed](#)]
- Combinations of opioid and cannabinoid agonists can induce synergistic analgesia in an animal experiencing acute pain. The extension of these studies to models of chronic pain is essential for evaluating the potential of combining therapies for this disease state.
37. Cichewicz DL, Haller VL, Welch SP. Changes in opioid and cannabinoid receptor protein following short-term combination treatment with delta(9)-tetrahydrocannabinol and morphine. *J Pharmacol Exp Ther.* 2001;297:121–127. [[PubMed](#)]
38. Rashid MH, Inoue M, Toda K, Ueda H. Loss of peripheral morphine analgesia contributes to the reduced effectiveness of systemic morphine in neuropathic pain. *J Pharmacol Exp Ther.* 2004;309:380–387. [[PubMed](#)]
39. Lim G, Sung B, Ji RR, Mao J. Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. *Pain.* 2003;105:275–283. [[PubMed](#)]
40. Mitirattanakul S, Ramakul N, Guerrero AV, Matsuka Y, Ono T, Iwase H, Mackie K, Faull KF, Spigelman I. Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. *Pain.* 2006;126:102–114. [[PMC free article](#)] [[PubMed](#)]
41. Walczak JS, Pichette V, Leblond F, Desbiens K, Beaulieu P. Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. *Neuroscience.* 2005;132:1093–1102. [[PubMed](#)]
42. Siegling A, Hofmann HA, Denzer D, Mauler F, De Vry J. Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain. *Eur J Pharmacol.* 2001;415:R5–R7. [[PubMed](#)]
43. Obara I, Parkitna JR, Korostynski M, Makuch W, Kaminska D, Przewlocka B, Przewlocki R. Local peripheral opioid effects and expression of opioid genes in the spinal cord and

dorsal root ganglia in neuropathic and inflammatory pain. *Pain*. 2009;141:283–291. [[PubMed](#)]

44. Zhang X, Bao L, Shi TJ, Ju G, Elde R, Hokfelt T. Down-regulation of mu-opioid receptors in rat and monkey dorsal root ganglion neurons and spinal cord after peripheral axotomy. *Neuroscience*.1998;82:223–240. [[PubMed](#)]

45. Puehler W, Zollner C, Brack A, Shaqura MA, Krause H, Schafer M, Stein C. Rapid upregulation of mu opioid receptor mRNA in dorsal root ganglia in response to peripheral inflammation depends on neuronal conduction. *Neuroscience*. 2004;129:473–479. [[PubMed](#)]

46. Besse D, Lombard MC, Perrot S, Besson JM. Regulation of opioid binding sites in the superficial dorsal horn of the rat spinal cord following loose ligation of the sciatic nerve: comparison with sciatic nerve section and lumbar dorsal rhizotomy. *Neuroscience*. 1992;50:921–933. [[PubMed](#)]

47. Ozaki S, Narita M, Narita M, Iino M, Miyoshi K, Suzuki T. Suppression of the morphine-induced rewarding effect and G-protein activation in the lower midbrain following nerve injury in the mouse: involvement of G-protein-coupled receptor kinase 2. *Neuroscience*. 2003;116:89–97. [[PubMed](#)]

48. Pol O, Murtra P, Caracuel L, Valverde O, Puig MM, Maldonado R Expression of opioid receptors and c-fos in CB1 knockout mice exposed to neuropathic pain. *Neuropharmacology*. 2006;50:123–132.[[PubMed](#)]

- Excellent study comparing changes in opioid and cannabinoid receptor expression in dorsal spinal cord of wild-type and CB<sub>1</sub>R knockout animals during the development of neuropathic pain. While MOR mRNA is decreased in both wild-type and CB<sub>1</sub>R knockout animals, DOR and KOR mRNA is unchanged after partial sciatic nerve lesion in both genotypes.

49. Wang Z, Gardell LR, Ossipov MH, Vanderah TW, Brennan MB, Hochgeschwender U, Hruby VJ, Malan TP, Jr, Lai J, Porreca F. Pronociceptive actions of dynorphin maintain chronic neuropathic pain. *J Neurosci*. 2001;21:1779–1786. [[PubMed](#)]

50. Sung B, Loh HH, Wei L. Association of kappa opioid receptor mRNA upregulation in dorsal root ganglia with mechanical allodynia in mice following nerve injury. *Neurosci Lett*. 2000;291:163–166.[[PubMed](#)]

51. Pickel VM, Chan J, Kash TL, Rodriguez JJ, MacKie K. Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens. *Neuroscience*. 2004;127:101–112. [[PubMed](#)]

52. Rodriguez JJ, Mackie K, Pickel VM. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. *J Neurosci.* 2001;21:823–833. [[PubMed](#)]
53. Kathmann M, Flau K, Redmer A, Trankle C, Schlicker E. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. *Naunyn Schmiedeberg's Arch Pharmacol.* 2006;372:354–361. [[PubMed](#)]
54. Vaysse PJ, Gardner EL, Zukin RS. Modulation of rat brain opioid receptors by cannabinoids. *J Pharmacol Exp Ther.* 1987;241:534–539. [[PubMed](#)]
55. Shapira M, Gafni M, Sarne Y. Independence of, and interactions between, cannabinoid and opioid signal transduction pathways in N18TG2 cells. *Brain Res.* 1998;806:26–35. [[PubMed](#)]
56. Rios C, Gomes I, Devi LA mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. *Br J Pharmacol.* 2006;148:387–395. [[PubMed](#)]
- First study to show direct, biophysical interactions between opioid and cannabinoid receptors, in co-transfected cells. The authors also find antagonistic interactions between the two receptor types in co-transfected cells and in native tissue exposed to increasing concentrations of an agonist to one receptor along with non-activating concentrations of an agonist of the other receptor.
57. Daniels DJ, Lenard NR, Etienne CL, Law PY, Roerig SC, Portoghese PS. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. *Proc Natl Acad Sci U S A.* 2005;102:19208–19213. [[PMC free article](#)] [[PubMed](#)]
58. Peng X, Knapp BI, Bidlack JM, Neumeyer JL. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors. *J Med Chem.* 2006;49:256–262. [[PubMed](#)]
59. Maekawa K, Minami M, Masuda T, Satoh M. Expression of mu- and kappa-, but not delta-, opioid receptor mRNAs is enhanced in the spinal dorsal horn of the arthritic rats. *Pain.* 1996;64:365–371. [[PubMed](#)]
60. Iadarola MJ, Brady LS, Draisci G, Dubner R. Enhancement of dynorphin gene expression in spinal cord following experimental inflammation: stimulus specificity, behavioral parameters and opioid receptor binding. *Pain.* 1988;35:313–326. [[PubMed](#)]
61. Millan MJ, Czlonkowski A, Morris B, Stein C, Arendt R, Huber A, Hollt V, Herz A. Inflammation of the hind limb as a model of unilateral, localized pain: influence on multiple opioid systems in the spinal cord of the rat. *Pain.* 1988;35:299–312. [[PubMed](#)]

62. Stevens CW, Kajander KC, Bennett GJ, Seybold VS. Bilateral and differential changes in spinal mu, delta and kappa opioid binding in rats with a painful, unilateral neuropathy. *Pain*. 1991;46:315–326. [[PubMed](#)]
63. Holdridge SV, Cahill CM. Spinal administration of a delta opioid receptor agonist attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. *Eur J Pain*. 2007;11:685–693. [[PubMed](#)]
64. Stone LS, Vulchanova L, Riedl MS, Williams FG, Wilcox GL, Elde R. Effects of peripheral nerve injury on delta opioid receptor (DOR) immunoreactivity in the rat spinal cord. *Neurosci Lett*. 2004;361:208–211. [[PubMed](#)]
65. Tseng TJ, Chen CC, Hsieh YL, Hsieh ST. Influences of surgical decompression on the dorsal horn after chronic constriction injury: changes in peptidergic and delta-opioid receptor (+) nerve terminals. *Neuroscience*. 2008;156:758–768. [[PubMed](#)]
66. Li JL, Kaneko T, Mizuno N. Effects of peripheral nerve ligation on expression of mu-opioid receptor in sensory ganglion neurons: an immunohistochemical study in dorsal root and nodose ganglion neurons of the rat. *Neurosci Lett*. 1996;214:91–94. [[PubMed](#)]
67. Truong W, Cheng C, Xu QG, Li XQ, Zochodne DW. Mu opioid receptors and analgesia at the site of a peripheral nerve injury. *Ann Neurol*. 2003;53:366–375. [[PubMed](#)]
68. Porreca F, Tang QB, Bian D, Riedl M, Elde R, Lai J. Spinal opioid mu receptor expression in lumbar spinal cord of rats following nerve injury. *Brain Res*. 1998;795:197–203. [[PubMed](#)]
69. Robertson B, Schulte G, Elde R, Grant G. Effects of sciatic nerve injuries on delta -opioid receptor and substance P immunoreactivities in the superficial dorsal horn of the rat. *Eur J Pain*. 1999;3:115–129. [[PubMed](#)]
70. Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O'Donnell D. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. *Eur J Neurosci*. 2003;17:2750–2754. [[PubMed](#)]